Device Center Says “522” Actions Are Up, But Industry Has No Cause To Worry
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center is increasingly emphasizing its ability to compel companies to collect specified postmarket surveillance data for marketed devices, according to Susan Gardner, director of the agency's Office of Surveillance & Biometrics
You may also be interested in...
Device Clinical Trial Compliance Hits 10-Year High – FDA’s Marcarelli
Compliance with FDA clinical trial rules is at its highest point in a decade, according to new statistics from the device center's Division of Bioresearch Monitoring
Device Clinical Trial Compliance Hits 10-Year High – FDA’s Marcarelli
Compliance with FDA clinical trial rules is at its highest point in a decade, according to new statistics from the device center's Division of Bioresearch Monitoring
Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data